Aliases & Classifications for Vaccinia

MalaCards integrated aliases for Vaccinia:

Name: Vaccinia 12 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:3298
MeSH 44 D014615
SNOMED-CT 68 111852003
UMLS 73 C0042214

Summaries for Vaccinia

Disease Ontology : 12 A viral infectious disease that results in infection, located in skin, has material basis in Vaccinia virus, which is used as a live vaccine against smallpox. The virus is transmitted by contact with the vaccination site before it has healed, or transmitted by fomites that have been contaminated with live virus from the vaccination site. The infection has symptom rash, has symptom fever, and has symptom body aches.

MalaCards based summary : Vaccinia is related to influenza and cowpox, and has symptoms including rash, fever and body aches. An important gene associated with Vaccinia is VRK1 (Vaccinia Related Kinase 1), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Influenza A. The drugs Vaccines and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include skin, prostate and t cells, and related phenotypes are hematopoietic system and immune system

Wikipedia : 76 Vaccinia virus (VACV or VV) is a large, complex, enveloped virus belonging to the poxvirus family. It... more...

Related Diseases for Vaccinia

Diseases related to Vaccinia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Related Disease Score Top Affiliating Genes
1 influenza 30.8 EIF2AK2 EIF2S1 IRF3 IRF7
2 cowpox 11.4
3 chromosome 2p16.1-p15 deletion syndrome 10.8 BANF1 VRK2
4 smallpox 10.6
5 monkeypox 10.3
6 eczema herpeticum 10.2 IRF3 IRF7
7 murray valley encephalitis 10.2 ERVW-1 IL2
8 encephalitis 10.1
9 human immunodeficiency virus type 1 10.1
10 type i 10.0
11 hepatitis 10.0
12 melanoma 10.0
13 dermatitis 10.0
14 dermatitis, atopic 9.9
15 mucositis 9.9
16 breast cancer 9.9
17 hepatocellular carcinoma 9.9
18 prostate cancer 9.9
19 prostatitis 9.9
20 pancreatitis 9.9
21 venezuelan equine encephalitis 9.9
22 stomatitis 9.9
23 viral infectious disease 9.9 EIF2AK2 ERVW-1 IL2 IRF3 IRF7
24 pancreatic cancer 9.9
25 malaria 9.9
26 rabies 9.9
27 hepatitis c 9.9
28 glioma 9.9
29 parainfluenza virus type 3 9.9
30 colorectal cancer 9.8
31 lung cancer 9.8
32 myeloma, multiple 9.8
33 hepatitis c virus 9.8
34 peritonitis 9.8
35 herpes simplex 9.8
36 measles 9.8
37 molluscum contagiosum 9.8
38 lassa fever 9.8
39 endotheliitis 9.8
40 ovarian cancer 9.7
41 aging 9.7
42 cervical cancer 9.7
43 dengue virus 9.7
44 arthritis 9.7
45 hepatitis b 9.7
46 tick-borne encephalitis 9.7
47 variola major 9.7
48 louping ill 9.7
49 sarcoma 9.7
50 lymphocytic choriomeningitis 9.7

Graphical network of the top 20 diseases related to Vaccinia:



Diseases related to Vaccinia

Symptoms & Phenotypes for Vaccinia

Symptoms:

12
  • rash
  • fever
  • body aches

MGI Mouse Phenotypes related to Vaccinia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 AZI2 BTRC DUSP3 EIF2AK2 EIF2S1 EPS15
2 immune system MP:0005387 9.32 AZI2 BTRC EIF2AK2 EPS15 IL2 IRF3

Drugs & Therapeutics for Vaccinia

Drugs for Vaccinia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 157)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
2 Antibodies Phase 4,Phase 2,Phase 1
3 gamma-Globulins Phase 4,Phase 2,Phase 1
4 Immunoglobulins Phase 4,Phase 2,Phase 1
5 Immunoglobulins, Intravenous Phase 4,Phase 2,Phase 1
6 Rho(D) Immune Globulin Phase 4,Phase 2,Phase 1
7
Sorafenib Approved, Investigational Phase 3,Phase 2 284461-73-0 216239 406563
8
Carboplatin Approved Phase 2, Phase 3,Not Applicable 41575-94-4 10339178 498142 38904
9
Cisplatin Approved Phase 2, Phase 3,Phase 1 15663-27-1 84093 441203 2767
10
Gemcitabine Approved Phase 2, Phase 3,Phase 1 95058-81-4 60750
11
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 33069-62-4 36314
12
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
13
Pemetrexed Approved, Investigational Phase 2, Phase 3 150399-23-8, 137281-23-3 446556 60843
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
15
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2 59-67-6 938
16
Nicotinamide Approved, Investigational, Nutraceutical Phase 3,Phase 2 98-92-0 936
17
leucovorin Approved, Nutraceutical Phase 2, Phase 3 58-05-9 143 6006
18 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
19 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
20 Analgesics Phase 3,Phase 2,Phase 1
21 Anticonvulsants Phase 3
22 Neurotropin Phase 3
23 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
24 Iron-Dextran Complex Phase 3,Phase 2
25 Krestin Phase 3,Phase 2,Phase 1
26 Micronutrients Phase 3,Phase 2
27 Nicotinic Acids Phase 3,Phase 2
28 Protein Kinase Inhibitors Phase 3,Phase 2
29 Trace Elements Phase 3,Phase 2
30 Vitamin B Complex Phase 3,Phase 2
31 Vitamins Phase 3,Phase 2
32 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 1,Not Applicable
33 Antimetabolites Phase 2, Phase 3,Phase 1
34 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
35 Antimitotic Agents Phase 2, Phase 3,Phase 1
36 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
37 Antiviral Agents Phase 2, Phase 3,Phase 1
38 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
39 Angiogenesis Inhibitors Phase 3,Phase 2
40 Angiogenesis Modulating Agents Phase 2, Phase 3
41
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
42 Folic Acid Antagonists Phase 2, Phase 3
43 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
44 Folate Nutraceutical Phase 3,Phase 2
45 Vitamin B3 Nutraceutical Phase 3,Phase 2
46 Vitamin B9 Nutraceutical Phase 3,Phase 2
47
Metronidazole Approved Phase 2,Phase 1,Not Applicable 443-48-1 4173
48
Bicalutamide Approved Phase 2 90357-06-5 56069 2375
49
Goserelin Approved Phase 2 65807-02-5 47725 5311128
50
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333

Interventional clinical trials:

(show top 50) (show all 249)
# Name Status NCT ID Phase Drugs
1 Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous(VIGIV) Completed NCT01158157 Phase 4
2 Special Access Program IMVAMUNE® Completed NCT03472014 Phase 4
3 The Protection Effect of Speeda® Rabies Vaccine for Human Use Completed NCT01827917 Phase 4
4 VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV Recruiting NCT02443623 Phase 4
5 A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Completed NCT01144637 Phase 3
6 Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
7 Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Completed NCT01317238 Phase 3 smallpox vaccine CJ-50300
8 Analgecine for the Treatment of Neuropathic Pain Completed NCT02633618 Phase 3
9 A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543567 Phase 3
10 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543268 Phase 3
11 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Recruiting NCT02562755 Phase 3 Sorafenib
12 IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
13 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 Recruiting NCT02509494 Phase 3
14 Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Recruiting NCT02661464 Phase 3
15 A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® Active, not recruiting NCT01913353 Phase 3
16 Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer Terminated NCT01383148 Phase 2, Phase 3 placebo
17 Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002817 Phase 1, Phase 2
18 Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers Unknown status NCT00103584 Phase 1, Phase 2
19 Evaluation and Treatment of Eye Complications of Vaccinia Vaccination Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
20 A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis Completed NCT01443260 Phase 1, Phase 2
21 Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma Completed NCT00116597 Phase 1, Phase 2
22 A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma Completed NCT00554372 Phase 2
23 A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
24 Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) Completed NCT01705223 Phase 2
25 A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
26 A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma Completed NCT00429312 Phase 1, Phase 2
27 High Dose IMVAMUNE® in Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
28 PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer Completed NCT00088413 Phase 2 Sargramostim (GM-CSF, Leukine)
29 A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer Completed NCT00108732 Phase 2 Bicalutamide;Goserelin Acetate
30 Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma Completed NCT01394939 Phase 1, Phase 2 Irinotecan
31 APSV in Vaccinia Naive Adults Completed NCT00050518 Phase 2
32 A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib Completed NCT01387555 Phase 2
33 Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT Completed NCT00038987 Phase 1, Phase 2
34 A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer Completed NCT01636284 Phase 2
35 A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma Completed NCT01171651 Phase 2 JX-594 followed by sorafenib
36 Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer Completed NCT00179309 Phase 2 Docetaxel
37 Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally Completed NCT00914732 Phase 2
38 ACAM 3000 MVA at Harvard Medical School Completed NCT00133575 Phase 1, Phase 2
39 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed NCT00019734 Phase 2
40 Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma Completed NCT00054535 Phase 2
41 Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Completed NCT00112957 Phase 2
42 Dressing Preparations for Smallpox Completed NCT00063856 Phase 1, Phase 2
43 A Study of MVA85A in Healthy Children and Infants Completed NCT00679159 Phase 2
44 Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors Completed NCT00003125 Phase 2
45 Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults Completed NCT00820846 Phase 2
46 MVA Post-Event: Administration Timing and Boost Study Completed NCT00437021 Phase 1, Phase 2 Placebo (subcutaneous);Placebo (scarification)
47 Safety Study of an Additional MVA Vaccine in Volunteers Who Received 3 DNA Vaccines Followed by 2 MVA Vaccines Completed NCT01461447 Phase 1, Phase 2
48 Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer Completed NCT00052351 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
49 Expanded Dryvax Dilution Study in Previously Vaccinated Adults Completed NCT00050505 Phase 2
50 Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Completed NCT00053495 Phase 2

Search NIH Clinical Center for Vaccinia

Cochrane evidence based reviews: vaccinia

Genetic Tests for Vaccinia

Anatomical Context for Vaccinia

The Foundational Model of Anatomy Ontology organs/tissues related to Vaccinia:

19
Skin

MalaCards organs/tissues related to Vaccinia:

41
Prostate, T Cells, Skin, Liver, Lung, Monocytes, Nk Cells

Publications for Vaccinia

Articles related to Vaccinia:

(show top 50) (show all 1166)
# Title Authors Year
1
<i>Tachypleus tridentatus</i> Lectin Enhances Oncolytic Vaccinia Virus Replication to Suppress In Vivo Hepatocellular Carcinoma Growth. ( 29880736 )
2018
2
Ocular Vaccinia Infection in Dairy Worker, Brazil. ( 29260673 )
2018
3
First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. ( 29669026 )
2018
4
Vaccinia virus in Feces and Urine of Wild Rodents from SALo Paulo State, Brazil. ( 29360742 )
2018
5
Antigenicity of <i>Leishmania</i>-Activated C-Kinase Antigen (LACK) in Human Peripheral Blood Mononuclear Cells, and Protective Effect of Prime-Boost Vaccination With pCI-neo-LACK Plus Attenuated LACK-Expressing Vaccinia Viruses in Hamsters. ( 29740446 )
2018
6
Vaccinia virus C9 ankyrin-repeat/F-box protein is a newly identified antagonist of the type I interferon-induced antiviral state. ( 29444943 )
2018
7
Genital Autoinoculation with Vaccinia: A Look at Two Cases. ( 29415160 )
2018
8
Vaccinia-based vaccines to biothreat and emerging viruses. ( 29779454 )
2018
9
Inhibition of vaccinia virus replication by nitazoxanide. ( 29625403 )
2018
10
High Initial Sputter Rate Found for Vaccinia Virions Using Isotopic Labeling, NanoSIMS, and AFM. ( 29295620 )
2018
11
Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms. ( 29259007 )
2018
12
E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox. ( 29300297 )
2018
13
Vaccinia Virus Protein C6: A Multifunctional Interferon Antagonist. ( 29785476 )
2018
14
In vitro susceptibility to ST-246 and Cidofovir corroborates the phylogenetic separation of Brazilian Vaccinia virus into two clades. ( 29427676 )
2018
15
Vaccinia Virus in Blood Samples of Humans, Domestic and Wild Mammals in Brazil. ( 29346277 )
2018
16
A Novel System for Constructing a Recombinant Highly-Attenuated Vaccinia Virus Strain (LC16m8) Expressing Foreign Genes and Its Application for the Generation of LC16m8-Based Vaccines against Herpes Simplex Virus 2. ( 29709968 )
2018
17
DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination. ( 29869530 )
2018
18
Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase. ( 29599502 )
2018
19
Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines. ( 29692427 )
2018
20
Septins suppress the release of vaccinia virus from infected cells. ( 29921601 )
2018
21
Lamin A/C augments Th1 differentiation and response against vaccinia virus and Leishmania major. ( 29311549 )
2018
22
The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host. ( 29678552 )
2018
23
Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-I94 with a Set of Gene Deletions on Several Viral Pathways. ( 29367944 )
2018
24
Weak vaccinia virus-induced NK cell regulation of CD4 T cells is associated with reduced NK cell differentiation and cytolytic activity. ( 29715623 )
2018
25
Mechanism of vaccinia viral protein B14-mediated inhibition of II_B kinase I^ activation. ( 29748387 )
2018
26
Molecular and Cellular Dynamics in the Skin, the Lymph Nodes, and the Blood of the Immune Response to Intradermal Injection of Modified Vaccinia Ankara Vaccine. ( 29922280 )
2018
27
Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis. ( 29773661 )
2018
28
<i>Haliotis discus discus</i> Sialic Acid-Binding Lectin Reduces the Oncolytic Vaccinia Virus Induced Toxicity in a Glioblastoma Mouse Model. ( 29701680 )
2018
29
Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against <i>Mycobacterium tuberculosis</i>. ( 29847865 )
2018
30
Mutagenic repair of double-stranded DNA breaks in vaccinia virus genomes requires cellular DNA ligase IV activity in the cytosol. ( 29676720 )
2018
31
A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge. ( 29339750 )
2018
32
A comparison of the effect of molluscum contagiosum virus MC159 and MC160 proteins on vaccinia virus virulence in intranasal and intradermal infection routes. ( 29393023 )
2018
33
Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. ( 29399394 )
2018
34
Discovery of a new class of inhibitors of Vaccinia virus based on (-)-borneol from A8bies sibA-rica and (+)-camphor. ( 29956885 )
2018
35
Labeling and Single-Particle-Tracking-Based Entry Mechanism Study of Vaccinia Virus from the Tiantan Strain. ( 29392930 )
2018
36
Immunisation of pigs by DNA prime and recombinant vaccinia virus boost to identify and rank African swine fever virus immunogenic and protective proteins. ( 29386289 )
2018
37
Vaccinia virus protein A49 activates Wnt signalling by targetting the E3 ligase I^-TrCP. ( 29058646 )
2017
38
Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles. ( 28331098 )
2017
39
Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells. ( 28951871 )
2017
40
Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development. ( 28057259 )
2017
41
Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins. ( 29257056 )
2017
42
Generation of Recombinant Vaccinia Viruses. ( 28060405 )
2017
43
Ecological niche modeling to determine potential niche of Vaccinia virus: a case only study. ( 28784125 )
2017
44
Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG(Ar)): a global review. ( 28938920 )
2017
45
Construction &amp;amp; establishment of two minigenome rescue systems for Chandipura virus driven by recombinant vaccinia virus expressing T7 polymerase. ( 28948956 )
2017
46
Improvement of in vivo expression of genes delivered by self-amplifying RNA using Vaccinia Virus immune evasion proteins. ( 28877647 )
2017
47
Temozolomide resistant human brain tumor stem cells are susceptible to recombinant vesicular stomatitis virus and double-deleted Vaccinia virus in vitro. ( 28931212 )
2017
48
Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine. ( 28241999 )
2017
49
Corrigendum to &amp;quot;Short communication: Survival of Vaccinia virus in inoculated cheeses during 60-day ripening&amp;quot; (J. Dairy Sci. 100:7051-7054). ( 28923659 )
2017
50
Tagging of the vaccinia virus protein F13 with mCherry causes aberrant virion morphogenesis. ( 28933687 )
2017

Variations for Vaccinia

Expression for Vaccinia

Search GEO for disease gene expression data for Vaccinia.

Pathways for Vaccinia

Pathways related to Vaccinia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 IL2 IRF3 IRF7 NLRP1 TANK
2
Show member pathways
12.45 EIF2AK2 EIF2S1 IL2 IRF3 IRF7
3
Show member pathways
12.39 AZI2 IRF3 IRF7 TANK TBKBP1
4 11.68 EIF2AK2 EIF2S1 IRF3 IRF7
5 11.61 IL2 IRF3 IRF7 NLRP1 TANK TBKBP1
6
Show member pathways
10.85 BANF1 VRK1 VRK2
7
Show member pathways
10.49 EIF2AK2 IRF3 IRF7

GO Terms for Vaccinia

Cellular components related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.83 AZI2 BANF1 BTRC DUSP3 EIF2AK2 EIF2S1
2 cytosol GO:0005829 9.47 BANF1 BTRC DUSP3 EIF2AK2 EIF2S1 EPS15

Biological processes related to Vaccinia according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.93 EIF2AK2 IL2 IRF3 IRF7 NLRP1
2 innate immune response GO:0045087 9.92 EIF2AK2 IRF3 IRF7 NLRP1 TBKBP1
3 Wnt signaling pathway GO:0016055 9.76 BTRC VRK1 VRK2 VRK3
4 membrane organization GO:0061024 9.74 EPS15 ITSN1 WASL
5 response to virus GO:0009615 9.73 BANF1 EIF2AK2 IRF7
6 protein autophosphorylation GO:0046777 9.73 EIF2AK2 EIF2S1 VRK1 VRK2
7 regulation of cell shape GO:0008360 9.71 VRK1 VRK2 VRK3 WASL
8 positive regulation of interferon-beta production GO:0032728 9.58 IRF3 IRF7
9 regulation of type I interferon production GO:0032479 9.55 IRF3 IRF7
10 positive regulation of interferon-alpha production GO:0032727 9.51 IRF3 IRF7
11 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.49 IRF3 IRF7
12 mitotic nuclear envelope reassembly GO:0007084 9.48 BANF1 VRK1
13 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.43 IRF3 IRF7 TANK
14 endocytosis GO:0006897 9.43 EPS15 ITSN1 VRK1 VRK2 VRK3 WASL
15 viral process GO:0016032 9.4 AZI2 BANF1 BTRC EIF2AK2 EPS15 IRF3
16 type I interferon biosynthetic process GO:0045351 9.37 IRF3 IRF7
17 MDA-5 signaling pathway GO:0039530 9.32 IRF3 IRF7
18 interferon-alpha production GO:0032607 9.16 AZI2 IRF7

Molecular functions related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 AZI2 BANF1 BTRC EIF2AK2 EIF2S1 EPS15
2 kinase activator activity GO:0019209 8.96 IL2 ITSN1

Sources for Vaccinia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....